HLB Cell Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.life-liver.co.kr
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 2:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Not Applicable
1 (33.3%)Study to Evaluate the Safety and Efficacy of HLBLS-200 in Patients Requiring Hemostatic Technique
Not Applicable
Completed
- Conditions
- Hemorrhage
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- HLB Cell Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT03957356
- Locations
- 🇰🇷
Hanyang Univ. Medical Center, Seoul, Korea, Republic of
A Safety and Efficacy Study of Infusions of HepaStem in Urea Cycle Disorders Pediatric Patients
Phase 2
Withdrawn
- Conditions
- Urea Cycle Disorder
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- HLB Cell Co., Ltd.
- Registration Number
- NCT03884959
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Study to Evaluate Safety and Efficacy of LifeLiver in Acute or Acute-on-Chronic Liver Failure Patients
Phase 2
- Conditions
- Acute-On-Chronic Liver FailureAcute Liver Failure
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- HLB Cell Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03882346
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
News
No news found